Zacks Investment Research
04 Dec 2025, 17:46 UTC · 41w ago
Verdict
Headline takes no side. We score IDXX +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
IDEXX Laboratories' Companion Animal Group (CAG) Diagnostics recurring revenues grew more than 10% organically in Q3 2025.
So whatStrong organic growth in the core recurring revenue stream indicates healthy demand and pricing power for the company.
More positive than 76% of claims this week
IDEXX Laboratories' stock has climbed 75.6% year-to-date, significantly outperforming the S&P 500's 18.5% gain.
So whatWhile reflecting past success, such extreme outperformance can signal either strong momentum or a valuation that is becoming stretched.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
More positive than 49% of claims this week
The company's active premium instruments installed base increased by 10%.
More positive than 49% of claims this week
IDEXX Laboratories currently holds a Zacks Rank #3 (Hold).
More positive than 40% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
The company has shown remarkable momentum, outperforming the S&P 500 with robust strategic execution and organic revenue growth.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
3d ago
−29.5%
Price is moving against the score
$511.65 vs $725.93 close before publication (Dec 3) · not market-adjusted
IDXX chart →
